Anacetrapib is another potent CETP inhibitor, demonstrated to raise HDL cholesterol by more than 130% and lower LDL cholesterol levels by 40%, in addition to enhancing cholesterol …

Anacetrapib. Anacetrapib is the third CETP inhibitor to be tested in human subjects. At its recommended daily dose of 100 mg, it more than doubles the concentration of HDL-C and …

Jun 1, 2017 · Evidence of persistent drug effects on LDL-C and HDL-C also were observed after completion of the 12-week safety follow-up period in patients who received anacetrapib (i.e., …

May 1, 2017 · The REVEAL study is a randomized, double-blind, placebo-controlled clinical trial that is assessing the efficacy and safety of adding anacetrapib to effective LDL-lowering …

Jun 5, 2015 · Anacetrapib 100 mg was well tolerated throughout the treatment phase, with no significant differences in prespecified safety variables compared with placebo—except for a …

Anacetrapib This new class of lipid-modifying drugs has substantial capacity to increase high-density lipoprotein (HDL) cholesterol, and anacetrapib was highly efficacious in a multicenter …

Feb 1, 2017 · Anacetrapib, but not evacetrapib reduced LDL levels by 25%, (Supplemental Fig. 5 and Supplemental Table 1). Likewise, the serum VLDL-triglyceride fraction was reduced in …

Dec 1, 2006 · Anacetrapib This new class of lipid-modifying drugs has substantial capacity to increase high-density lipoprotein (HDL) cholesterol, and anacetrapib was highly efficacious in …

Jan 1, 2023 · Anacetrapib increased the level of apo E found in apo B-depleted plasma by 57% (P < 0.05) and 48% (P < 0.05) when administered in the absence or presence or atorvastatin, …

Nov 1, 2015 · Anacetrapib decreases PCSK9 mRNA expression and plasma levels and increases hepatic LDLr protein expression. Female E3L.CETP MICE were fed a Western-type diet with …